Shares of Eli Lilly & Co. were headed for their worst day in nearly four years on Tuesday after the drugmaker provided a fourth-quarter revenue outlook that was below expectations, citing slower ...

Eli Lilly pre-announced a sizable Q4 2024 revenue miss headed into the big J.P. Morgan healthcare investor conference, but the biopharma reported massive growth. A lot of the quarterly ...

Government policies and regulations are uncontrollable and the good news is that for a business such as Eli Lilly, which is developing potentially life-changing treatments for patients ...

Tim Smith has 20+ years of experience in the financial services industry, both as a writer and as a trader. Eli Lilly shares could remain under the microscope on Wednesday after falling sharply ...

Eli Lilly and Company (NYSE:LLY) shares slid 6.6% to $744.91, after it said it expects Q4 revenue at $13.5 billion- weaker than street expectations of $14.08 billion. The miss was driven largely ...

SAN FRANCISCO — When Eli Lilly last year started offering lower-priced vials of its blockbuster obesity drug Zepbound, which were previously sold in injectable pens, it framed the move as a way ...

Eli Lilly announced preliminary fourth-quarter ... such as portfolio management or data aggregation. Develop and improve features of our offerings. Gear advertisements and other marketing efforts ...

That’s how much Eli Lilly’s revenue grew in 2024, but it was still not as much as the company or investors expected, which had CEO David Ricks trying to assuage investors. Lilly on Tuesday ...

Like many other biopharma companies presenting at this year’s J.P. Morgan Healthcare Conference, Eli Lilly took a chance on Tuesday to share its preliminary sales results for 2024. Unfortunately ...

Ore Huiying / Bloomberg / Getty Images Eli Lilly shares tumbled Tuesday after the drugmaker lowered its revenue forecast for the 2024 fiscal year. The maker of weight-loss drugs Mounjaro and ...

Eli Lilly & Co.’s fourth-quarter revenue fell short of analysts’ estimates as the drugmaker struggled to forecast demand for its popular weight-loss and diabetes shots for the second quarter ...